摘要
目的观察早期尿激酶静脉溶栓治疗急性心肌梗死(AMI)的疗效。方法回顾分析24例采用早期尿激酶溶栓治疗与18例采用常规治疗的AMI患者的临床资料,观察溶栓治疗患者的再通情况及溶栓后24h内T波倒置对判断冠脉再通的影响。结果尿激酶治疗组和常规治疗组的冠脉再通率分别为62.5%和15.0%(P<0.05),发病至开始溶栓的时间越短,再通率越高。结论早期尿激酶静脉溶栓治疗可提高AMI疗效,降低病死率,宜早期应用。
Objective To observe the therapeutic effect of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction （AMI）. Method The clinic data of 24 patients treated with early stage thrombolytic therapy with venous urokinase and 18 conventional therpy were reviewed, and the repatency of the coronary artery and T-wave inversion within 24 h after the treatment were evaluate. Result The repatency rate of urokinase group and conventional therapy group was 62.5% and 15.0%, respectively, showing significant difference （P〈0.05）. Shorter delay of administration of thrombolytic therapy after infarction onset resulted in higher rate ofrepatency. Conclusion Early stage thrombolytic therapy with venous urokinase can improve the therapeutic effect and reduce the mortality rate of AMI, and is therefore recommended for clinical application.
出处
《第一军医大学学报》
CSCD
北大核心
2005年第11期1452-1453,共2页
Journal of First Military Medical University
关键词
尿激酶
血栓溶解疗法
急性心肌梗死/治疗
urokinase
thrombolytic therapy
acute myocardial infarction/therapy
